Gilles Paintaud

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

Édouard Louis, Jean‐Yves Mary, Gwénola Vernier-Massouille et al. · Gastroenterology · 2011 · 593 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

Gert Van Assche, Charlotte Magdelaine–Beuzelin, Geert D’Haens et al. · Gastroenterology · 2008 · 497 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

Konstantinos Κarmiris, Gilles Paintaud, Maja Noman et al. · Gastroenterology · 2009 · 478 citations · Full text

Life Sciences, Clinical Sciences, Immunology +16

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Sébastien Dall’Ozzo, Sophie Tartas, Gilles Paintaud et al. · Cancer Research · 2004 · 417 citations

Life Sciences, Cell Biology, Immunology +17

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Sophie Dupuis‐Girod, Isabelle Ginon, Jean‐Christophe Saurin et al. · JAMA · 2012 · 384 citations

Medicine, Cardiology, Pharmacotherapy +13